Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging.

Abstract

PURPOSE Little is known concerning the onset, duration, and magnitude of direct therapeutic effects of anti-vascular endothelial growth factor (VEGF) therapies. Such knowledge would help guide the rational development of targeted therapeutics from bench to bedside and optimize use of imaging technologies that quantify tumor function in early-phase clinical… (More)
DOI: 10.1158/1078-0432.CCR-09-0731

Topics

6 Figures and Tables

Cite this paper

@article{OConnor2009QuantifyingAE, title={Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging.}, author={J. P. B. O'Connor and Richard A D Carano and Andrew R. Clamp and Jed Ross and Calvin C. K. Ho and Alan Jackson and Geoffrey J. M. Parker and C. J. Rose and Franklin V. Peale and Michel J Friesenhahn and Claire L. Mitchell and Yvonne Watson and Caleb Roberts and Lynn Hope and Sue Cheung and Hani Bou Reslan and Mary Ann T. Go and Glenn J. Pacheco and Xiumin Wu and Tim C. Cao and Sarajane Ross and Giovanni A. Buonaccorsi and Karen Davies and Jurjees Hasan and Paula Thornton and Olivia del Puerto and Napoleone M A Ferrara and Nicholas van Bruggen and Gordon C. Jayson}, journal={Clinical cancer research : an official journal of the American Association for Cancer Research}, year={2009}, volume={15 21}, pages={6674-82} }